AJMC April 11, 2025
Key Takeaways
- Blinatumomab combined with chemotherapy increased disease-free survival by 61% in children with B-cell acute lymphoblastic leukemia.
- Hispanic children, who often face worse outcomes, saw a 71% survival benefit with the new regimen.
- The IKF1 gene variant, prevalent among those of indigenous American ancestry, may contribute to poorer outcomes in Hispanic children.
- These findings highlight significant progress in addressing treatment disparities in pediatric leukemia.
In December 2024, Rachel E. Rau, MD, brightened when asked about data that showed a new regimen for pediatric leukemia worked exceptionally well in Hispanic children.1
Rau, an associate professor of pediatrics at Seattle Children’s, shared results that showed adding blinatumomab (Blincyto; Amgen Inc) to chemotherapy boosted disease-free survival by 61% in children...
Today's Sponsors
Today's Sponsor